Karyopharm files for Chapter 11, agrees to merge with Ayrmid
What's the deal? Karyopharm Therapeutics, a Massachusetts-based cancer-drug maker, has filed for Chapter 11 bankruptcy and agreed to merge with Ireland's Ayrmid in a court-supervised sale. Ayrmid will serve as lead bidder, and the deal is expected to close in the first quarter of 2027. Terms were not disclosed.
Why now? Karyopharm has been squeezed by a worsening liquidity crisis. A $30 million placement with RA Capital in March was expected to fund operations only into late in the third quarter, and by October the company was leaning on lender forbearance amid defaults and warnings it might not continue as a going concern.
What's the endgame? The reorganisation aims to preserve Karyopharm's marketed products and its pipeline in multiple myeloma and myelofibrosis. Karyopharm has secured commitments for up to $55 million in debtor-in-possession financing from existing secured lenders to keep operations running through the process, subject to court approval.
Ayrmid, led by chairman and chief executive officer Joe Wiley, develops therapies for blood disorders. "We see a strong strategic fit between Ayrmid and Karyopharm, with complementary portfolios, established commercial capabilities and a shared commitment to addressing significant unmet needs in hematology," Wiley said.
What could go wrong? The outcome is not settled. The company will seek court approval of bidding procedures that allow rival parties to submit competing proposals, so Ayrmid may not prevail. The merger remains subject to the conditions of the Chapter 11 plan and court approval.
Richard Paulson, Karyopharm's president and chief executive officer, framed the filing as a path to salvage value. "Following a comprehensive review of available alternatives, we believe this process provides a clear framework to pursue a value maximizing transaction for our stakeholders," he said.
The signal: This is less a strategic tie-up than a rescue through restructuring. For commercial-stage biotechs running short on cash, a court-supervised sale is becoming a route to keep marketed drugs and pipelines alive — and to hand them to a better-funded buyer rather than wind them down.
Read more: prnewswire.com
Image credit: Karyopharm Therapeutics
